ARWR Arrowhead Pharmaceuticals completes enrollment in global phase 3 yosemite study of zodasiran for the treatment of homozygous familial h
ARWR Arrowhead Pharmaceuticals completes enrollment in global phase 3 yosemite study of zodasiran for the treatment of homozygous familial hypercholesterolemia Arrowhead Pharmaceuticals - yosemite phase 3 study completion anticipated in mid-2027
Story updates
11:31:50 AM UTC
SquawkNews
ARWR Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
11:33:10 AM UTC
SquawkNews
ARWR - Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.